NCT00648713已完成1 期
Single-Dose Food In Vivo Bioequivalence Study of Terbinafine Hydrochloride Tablets (250 mg; Mylan) and Lamisil® (250 mg; Novartis) in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Bioequivalence
研究概览
简要总结
The objective of this study was to investigate the bioequivalence of Mylan's terbinafine hydrochloride tablets to Novartis' Lamisil® tablets following a single, oral 250 mg (1 x 250 mg) dose administered under fed conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age: 18 years and older.
- •Sex: Male and/or non-pregnant, non-lactating female.
- •Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration. If dosing is scheduled on weekends, the HCG pregnancy test should be given within 48 hours prior to dosing of each study period. An additional serum (beta-HCG) pregnancy test will be performed upon completion of the study.
- •Women of childbearing potential must practice abstinence or be using an acceptable form of contraception throughout the duration of the study. No hormonal contraceptives or hormone replacement therapy are permitted in this study. Acceptable forms of contraception include the following:
- •intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or
- •barrier methods containing or used in conjunction with a spermicidal agent, or
- •surgical sterility (tubal ligation, oophorectomy or hysterectomy) or postmenopausal accompanied with a documented postmenopausal course of at least one year.
- •During the course of the study, from study screen until study exit - including the washout period, women of childbearing potential must use a spermicide containing barrier method of contraception in addition to their current contraceptive device. This advice should be documented in the informed consent form.
- •Weight: At least 60 kg (132 lbs) for men and 48 kg (106 lbs) for women and all subjects within 15% of Ideal Body Weight (IBW), as referenced by the Table of "Desirable Weights of Adults" Metropolitan Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
- •All subjects should be judged normal and healthy during a pre-study medical evaluation (physical examination, laboratory evaluation, hepatitis B and hepatitis C tests, HIV test, 12-lead ECG, and urine drug screen including amphetamine, barbiturates, benzodiazepines, cannabinoid, cocaine, opiate screen, phencyclidine, and methadone) performed within 14 days of the initial dose of study medication.
排除标准
- •Institutionalized subjects will not be used.
- •Social Habits:
- •Use of any tobacco products within 1 year of the start of the study.
- •Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication.
- •Ingestion of any vitamins or herbal products within the 7 days prior to the initial dose of the study medication.
- •Any recent, significant change in dietary or exercise habits.
- •A positive test for any drug included in the urine drug screen.
- •History of drug and/or alcohol abuse.
- •Medications:
- •Use of any prescription or over-the-counter (OTC) medications within the 14 days prior to the initial dose of study medication.
- •Use of any hormonal contraceptives and hormone replacement therapy within 3 months prior to study medication dosing.
- •Use of any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication.
- •History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic disease.
- •Acute illness at the time of either the pre-study medical evaluation or dosing.
- •A positive HIV, hepatitis B, or hepatitis C test.
- •Chronic or active liver disease.
- •Abnormal and clinically significant laboratory test results:
- •Clinically significant deviation from the Guide to Clinically Relevant Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
- •Abnormal and clinically relevant ECG tracing.
- •Outside normal range AST, ALT, alkaline phosphatase, and/or total bilirubin laboratory results.
- •Donation or loss of a significant volume of blood or plasma (> 450 mL) within 28 days prior to the initial dose of study medication.
- •Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.
- •Allergy or hypersensitivity to terbinafine or any other related drugs.
- •History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption.
- •Consumption of grapefruit or grapefruit containing products within 7 days of drug administration.
研究组 & 干预措施
1
Experimental
Terbinafine Hydrochloride Tablets 250 mg
干预措施: Terbinafine Hydrochloride Tablets 250 mg (Drug)
2
Active Comparator
Lamisil® Tablets 250 mg
干预措施: Lamisil® Tablets 250 mg (Drug)
结局指标
主要结局
Bioequivalence
时间窗: within 30 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mgHealthyNCT00647647Mylan Pharmaceuticals Inc36
已完成
1 期
Food BE Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage XR 500 mgHealthyNCT00649948Mylan Pharmaceuticals Inc27
已完成
1 期
Food Study Metformin Hydrochloride ER Tablets 750 mg and Glucophage XR 750 mgHealthyNCT00649350Mylan Pharmaceuticals Inc28
已完成
1 期
Food Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mgHealthyNCT00648440Mylan Pharmaceuticals Inc36
已完成
1 期
Fed Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mgHealthyNCT00650013Mylan Pharmaceuticals Inc23